![Fig. 5. Clinical relevance of CYP2D6 genotype on β-blocker treatment. Poor CYP2D6 metabolizers experience a greater reduction in heart rate (a) and a higher risk of bradycardia when treated with metoprolol. HR = heart rate; PM = poor metabolizer. Reprinted with permission from Macmillan Publishers Ltd.: [Clinical Pharmacology & Therapeutics] Rau T et al. , Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study 2009; 85:269–72.](https://asa2.silverchair-cdn.com/asa2/content_public/journal/anesthesiology/115/6/10.1097_aln.0b013e3182315eb2/2/32ff5.png?Expires=1716495189&Signature=E-7rdTKIc8on-7rcoIEaW~otTeAQfVS3Q40G~KNrYFQizVBCkadNIMzsAjbXqnb4me-iPLtyEHZYEn1G37mC4byburtgmDDuk-eAKV2DWHXkx07PGcsxnST2hnIvj0nj~E64uT-KZfRDQjtnLMLxQyI01~Kci2vPe3DNbn34FRvti0zPmjvy51EII7OnJVuBUxdY-SO3IUv-bO8P-PG9oLdmWX7QUjql9NZaleIG0AadXhq5fYBdhkR4TLNAjUtIuV3oA4LwHTmrxQ1dqvJ9wU39bnTACu3zyeBb1wZS4f37L1ef0zJ458IBOOxJYVMrbB11dvF6CyPXJEqaU70X3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Fig. 5. Clinical relevance of CYP2D6 genotype on β-blocker treatment. Poor CYP2D6 metabolizers experience a greater reduction in heart rate (a) and a higher risk of bradycardia when treated with metoprolol. HR = heart rate; PM = poor metabolizer. Reprinted with permission from Macmillan Publishers Ltd.: [Clinical Pharmacology & Therapeutics] Rau T et al. , Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study 2009; 85:269–72.
